Call Options

3 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2020

Nov 16, 2020

SELL
$4.32 - $11.7 $2,592 - $7,020
-600 Closed
0 $0
Q2 2020

Aug 14, 2020

BUY
$2.94 - $9.1 $588 - $1,820
200 Added 50.0%
600 $5,000
Q4 2018

Feb 14, 2019

BUY
$8.14 - $13.28 $3,256 - $5,312
400 New
400 $4,000

Others Institutions Holding DVAX

About DYNAVAX TECHNOLOGIES CORP


  • Ticker DVAX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 126,474,000
  • Market Cap $1.42B
  • Description
  • Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufa...
More about DVAX
Track This Portfolio

Track Prelude Capital Management, LLC Portfolio

Follow Prelude Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Prelude Capital Management, LLC with notifications on news.